2007至2023年美国新诊断儿童克罗恩病与溃疡性结肠炎治疗模式演变及临床结局
基于OptumLabs数据库的起始队列,纳入2007-23年新诊断的787例儿童克罗恩病(CD)和399例溃疡性结肠炎(UC)患者,分析治疗模式与临床结局。结果显示,2019-23年诊断的CD和UC患儿早期使用先进疗法的比例显著增加,CD住院风险降低,但两种疾病的手术风险均未显著下降;研究未发现一致的种族、年龄或性别差异。
要点
- 儿童IBD早期先进疗法使用显著增加,CD的2019-23年vs 2007-12年aHR为3.43。
- CD患儿5年住院和手术风险分别为30%和10%;UC分别为36%和8%。
- CD患儿2019-23年诊断者住院风险降低(aHR 0.65),手术风险未显著下降。
核心结论
- 在商业保险儿童IBD队列中,早期先进疗法使用显著增加,CD住院风险降低但手术风险未显著下降,UC住院和手术风险无显著变化。
研究设计与样本
- 使用OptumLabs Data Warehouse构建2007-23年6-17岁新诊断IBD儿童的起始队列,分析CD 787例和UC 399例。
主要发现
- CD患儿5年IBD相关住院和重大手术风险分别为30%和10%,UC患儿5年住院和结肠切除术风险分别为36%和8%。
- CD患儿2019-23年诊断者1年累积激素使用46%、先进疗法使用75%;先进疗法使用随时间显著增加(aHR 3.43,95%CI 2.71-4.32),激素使用下降(0.67,0.53-0.84)。
- CD患儿2019-23年诊断者住院风险低于2007-12年诊断者(aHR 0.65,95%CI 0.43-0.97),手术风险未显著下降。
- UC患儿先进疗法使用随时间显著增加(aHR 4.46,95%CI 2.85-6.98),住院和手术风险无显著变化。
- 未发现一致的种族、民族、年龄或性别差异。
临床怎么用
- 临床实践中应关注儿童IBD早期先进疗法的应用趋势,并个体化评估手术风险。
局限性
- 研究未针对排除临床有意义的手术风险降低进行效能计算,结果仅为假设生成性而非结论性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AIMS: We examined treatment patterns and clinical outcomes in a contemporary cohort of children with newly diagnosed inflammatory bowel disease (IBD) in a large, commercially insured U.S. population. METHODS: Using the OptumLabs® Data Warehouse, we created an inception cohort of physician-diagnosed IBD in children aged 6-17 years between 2007-23. We examined cumulative incidence of hospitalization, surgery, safety events, and medication use in patients with Crohn's disease (CD) and ulcerative colitis (UC), overall and stratified by diagnostic era, race and ethnicity, sex, and age at diagnosis. RESULTS: Among 787 children with newly diagnosed CD (age at diagnosis, 13.4±2.9y; 57% male; 82% White, 5% Black, 7% Hispanic) followed over mean 4.6±3.0y, 5-year risk of IBD-related hospitalization and major surgery was 30% and 10%, respectively. In children diagnosed in 2019-23, 1-year cumulative use of corticosteroids and advanced therapy was 46% and 75%, respectively; advanced therapy use increased significantly over time (aHR, 3.43 [95% CI, 2.71-4.32] for 2019-23 vs. 2007-12), while corticosteroid use declined (0.67 [0.53-0.84]). Risk of IBD-related hospitalization was lower in children diagnosed between 2019-23 (0.65 [0.43-0.97]) compared with those diagnosed between 2007-12; surgical risk did not decline significantly, with confidence intervals compatible with a clinically meaningful reduction. Among 399 children with newly diagnosed UC (age at diagnosis, 14.0±3.0y; 53% male; 78% White, 5% Black, 7% Hispanic) followed over 4.5±3.0y, 5-year risk of IBD-related hospitalization and colectomy was 36% and 8%, respectively. Advanced therapy use increased significantly over time (4.46 [2.85-6.98] for 2019-23 vs. 2007-12), with no significant change in hospitalization or surgical risk across eras. No consistent racial and ethnic, age, or sex differences in advanced therapy use or clinical outcomes were identified in either CD or UC. CONCLUSIONS: In a contemporary cohort of commercially insured children with newly diagnosed IBD, early advanced therapy use has increased markedly over time. Surgical risk did not decline significantly in either disease; however, the study was not powered to exclude a clinically meaningful reduction, and these findings are hypothesis-generating rather than conclusive.
引用
- Gonzalez MM, Ahuja D, Qi Y, et al. Evolving Treatment Patterns and Clinical Outcomes in Children with Newly Diagnosed Crohn's Disease and Ulcerative Colitis in the United States, 2007-2023. Am J Gastroenterol. 2026. PMID: 42841617. doi:10.14309/ajg.0000000000004219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。